Anti-hyperglycemic action of apigenin-6-C-β-fucopyranoside from Averrhoa carambola.
A stimulatory effect of apigenin-6-C-β-fucopyranoside (1) on glucose uptake was observed when rat soleus muscle was incubated with 1, 10 and 100 μM of this flavonoid glycoside. The presence of specific insulin signaling inhibitors, such as wortmannin, an inhibitor of phosphoinositide 3-kinase (PI3K), RO318220, an inhibitor of protein kinase C (PKC), PD98059, an inhibitor of mitogen-activated protein kinase (MEK), and HNMPA(AM)₃, an insulin receptor tyrosine kinase activity inhibitor showed that apigenin-6-C-β-fucopyranoside triggers different metabolic pathways in skeletal muscle. The oral administration of crude extract, fractions and isolated flavonoids (apigenin-6-C-β-fucopyranoside (1) and apigenin-6-C-(2″-O-α-rhamnopyranosyl)-β-fucopyranoside (2)) from Averrhoa carambola leaves exhibited a potential hypoglycemic activity in hyperglycemic normal rats. Additionally, both flavonoids significantly increased the muscle and liver glycogen content after an acute treatment. The results indicate that A. carambola can be regarded as a potent antihyperglycemic agent with insulin secretagogue and insulin mimetic properties.
Universidade Federal da Fronteira Sul, Campus Universitário Laranjeiras do Sul, Bairro Vila Alberti, CEP 85303-775, Laranjeiras do Sul, PR, Brazil.
Luisa Helena
LH
Cazarolli
Virgínia Demarchi
VD
Kappel
Danielle Fontana
DF
Pereira
Henrique Hunger
HH
Moresco
Inês Maria Costa
IM
Brighente
Moacir Geraldo
MG
Pizzolatti
Fátima Regina Mena Barreto
FR
Silva
D000284:Administration, Oral; D000818:Animals; D047310:Apigenin / Q000494:pharmacology / Q000627:therapeutic use*; D005947:Glucose / Q000378:metabolism*; D006003:Glycogen / Q000378:metabolism; D006027:Glycosides / Q000494:pharmacology / Q000627:therapeutic use*; D006943:Hyperglycemia / Q000188:drug therapy* / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D019684:Magnoliopsida / Q000737:chemistry*; D008297:Male; D053858:Metabolic Networks and Pathways / Q000187:drug effects; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D018482:Muscle, Skeletal; D000081082:Phosphoinositide-3 Kinase Inhibitors; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D018515:Plant Leaves; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction / Q000187:drug effects
D006027:Glycosides; D007004:Hypoglycemic Agents; D007328:Insulin; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010936:Plant Extracts; C546678:apigenin-6-C-beta-L-fucopyranoside; D047310:Apigenin; D006003:Glycogen; C410467:insulin receptor tyrosine kinase; D011505:Protein-Tyrosine Kinases; D011493:Protein Kinase C; D020928:Mitogen-Activated Protein Kinases; D005947:Glucose